COVID-19, heavy drinking and alcohol use disorders: a national study of Veterans Administration patients
COVID-19、酗酒和酒精使用障碍:一项针对退伍军人管理局患者的全国研究
基本信息
- 批准号:10596115
- 负责人:
- 金额:$ 18.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-04-01 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAcute Respiratory Distress SyndromeAddressAffectAgeAlcohol consumptionAlcoholsBackBehavioralBig DataBiologicalBlack PopulationsBlack raceCOVID-19COVID-19 prognosisCOVID-19 riskCOVID-19 severityCOVID-19 susceptibilityCOVID-19 vaccinationCaringCause of DeathCessation of lifeCharacteristicsChronicComputerized Medical RecordCountyDataDatabasesDiabetes MellitusDiagnosisDiagnosticDisastersDiseaseEthnic OriginEventExploratory/Developmental GrantFundingFutureGeneral PopulationHealthHealth behaviorHeavy DrinkingHispanicHispanic PopulationsHospitalizationHypertensionICD-10-CMImmune responseImmune systemImpairmentIndividualInfectionIntensive CareKnowledgeLinkLogistic RegressionsMedicalMedicareMinorityMisinformationModelingNational Institute on Alcohol Abuse and AlcoholismObesityOutcomePatientsPersonsPneumoniaPoliciesPovertyPrevalencePreventiveProcessPrognosisProviderRaceResearch InfrastructureRetrospective cohortRiskSARS-CoV-2 exposureSARS-CoV-2 infectionSARS-CoV-2 negativeScientistServicesSocial EnvironmentStatistical Data InterpretationStressTestingTimeUnited States Department of Veterans AffairsVaccinatedVaccinationVaccinesVeteransVirus DiseasesVital Statusalcohol effectalcohol screeningalcohol use disordercopingcostdata repositorydata resourcedata sharingdata sharing networksdemographicsdesigndrinkingelectronic medical record systemhousing instabilityhuman old age (65+)indexinginfection riskinterestmalemenmortalitynovel coronaviruspandemic diseaseresidenceservice providerssexsociodemographicsvaccine distributionvaccine hesitancy
项目摘要
Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV-2 is a global pandemic. While most COVID-19
cases are mild or moderate, severe cases (~15%) require hospitalization, critical cases (~5%) require intensive
care, and many deaths occur. Males, Blacks and Hispanics are at greater risk for COVID-19 infection, and poor
prognosis is predicted by older age, race/ethnicity, and prior underlying medical conditions. A potentially critical
factor not yet studied is heavy alcohol use or alcohol use disorder (AU/AUD). AU/AUD could increase the risk
for COVID-19 infection and poor prognosis through poor health behaviors, by direct effects of alcohol on the
immune system, or by indirect effects due to the greater prevalence of underlying medical conditions that predict
poor COVID-19 prognosis. Little is known about the relationship of AU/AUD to the likelihood of COVID-19
vaccination, infection, or poor prognosis, and if these relationships are modified by medical conditions (e.g.,
hypertension, obesity, diabetes), spatially-defined socioenvironmental or exposure variables (e.g., county
poverty or COVID-19 rates) or demographic characteristics (sex, age, race/ethnicity, poverty). To study this,
large databases are needed that include AU/AUD, demographic characteristics, spatial identifiers, diagnostic,
treatment and mortality information. Responding to PA-20-195 (and addressing issues in NOT-AA-20-011), we
will utilize the Veterans Administration (VA) Electronic Medical Record (EMR) system for this purpose. The VA
treats 6.3 million veterans a year. VA patients have high rates of COVID-19 vulnerability factors, e.g., male, older
age, chronic medical conditions. A VA Shared Data Resource identifies COVID-19 cases (now N=186,174, with
9,299 deaths). The many VA patients with ICD-10-CM AUD or positive alcohol (AUDIT-C) screens provide
extensive data on whether the likelihood of COVID-19 outcomes differ by AU/AUD status. Leveraging a research
infrastructure established in an existing project, we propose a 2-year study to comprehensively address the
relationship of AU/AUD to COVID-19 vaccination, infection and prognosis, and how these relationships are
affected by demographic, medical, spatial exposure characteristics. Aim1: Determine the relationship of AU/AUD
to COVID-19 vaccination, infection, and in those infected, poor prognosis (e.g., hospitalization, ICU treatment,
death). Aim 2: Determine if associations of AU/AUD with COVID-19 outcomes vary over time, medical conditions
(e.g., hypertension, obesity, diabetes), spatial exposures or demographic characteristics. In Year 01, we will
analyze EMR diagnostic, treatment, and vital status death data, using a 12-month lookback period to determine
AU/AUD and medical conditions that preceded COVID-19 outcome variables. In Year 02, we will incorporate
National Death Index data to examine causes of death, and expand information on veterans ≥age 65 with
Medicare data. Logistic regression will evaluate differences in COVID-19 outcomes by AU/AUD status. Among
those with COVID-19, survival models will determine if time to poor prognosis events differs by AU/AUD. Results
will fill major gaps in knowledge about the risks for and prognosis of COVID-19 among those with AU/AUD.
SARS-COV-2引起的冠状病毒疾病2019年(Covid-19)是全球大流行。而大多数covid-19
病例是轻度或中等,严重病例(约15%)需要住院,关键病例(约5%)需要密集
护理,发生许多死亡。男性,黑人和西班牙裔人患相互vid-19感染的风险更大,而且很差
预后由年龄,种族/种族和先前的基本医疗状况预测。潜在的关键
尚未研究的因素是大量饮酒或酒精使用障碍(AU/AUD)。 AU/AUD可能会增加风险
通过不良的健康行为,通过酒精对健康行为不良的感染和预后不良,直接影响酒精对
免疫系统或由于预测潜在的医疗状况的较高流行率而受到间接影响
covid-19-19的预后不良。关于AU/AUD与Covid-19的可能性的关系知之甚少
疫苗接种,感染或预后不良,如果这些关系是通过医疗状况改变的(例如,
高血压,肥胖,糖尿病),空间定义的社会环境或暴露变量(例如,县
贫困或共同率-19率)或人口特征(性别,年龄,种族/种族,贫困)。为了研究这一点,
需要大型数据库,其中包括AU/AUD,人口统计学特征,空间标识符,诊断,
治疗和死亡率信息。在回应PA-20-195(以及在Not-AA-20-011中解决问题)时,我们
将出于这个目的,将利用退伍军人管理(VA)电子病历(EMR)系统。 VA
每年对630万退伍军人进行待遇。 VA患者的共同漏洞因素较高,例如男性,年龄较大
年龄,慢性医疗状况。 VA共享数据资源标识了Covid-19情况(现在n = 186,174,
9,299人死亡)。 ICD-10-CM AUD或阳性酒精(审核-C)筛查的许多VA患者提供
关于Covid-19结果的可能性是否与AU/AUD状态不同的广泛数据。利用研究
在现有项目中建立的基础设施,我们提出了一项为期两年的研究,以全面解决
AU/AUD与COVID-19疫苗接种,感染和预后以及这些关系的关系
受人口统计学,医学,空间暴露特征的影响。 AIM1:确定AU/AUD的关系
与19次疫苗接种,感染和感染者预后不良(例如,住院,ICU治疗,
死亡)。目标2:确定AU/AUD与Covid-19结果的关联是否随着时间的流逝而变化
(例如,高血压,肥胖,糖尿病),空间暴露或人口统计学特征。在01年,我们将
使用12个月的回顾期分析EMR诊断,治疗和生命状态死亡数据
AU/AUD和医疗条件在COVID-19结果变量之前。在02年,我们将合并
国家死亡指数数据以检查死亡原因,并扩展有关退伍军人≥65的信息
Medicare数据。逻辑回归将通过AU/AUD状态评估Covid-19结果的差异。之中
那些患有COVID-19的人,生存模型将确定预后事件不良的时间是否有AU/AUD的不同。结果
在知道AU/AUD的人群中,Covid-19的风险和预后将填补主要空白。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DEBORAH S HASIN其他文献
DEBORAH S HASIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DEBORAH S HASIN', 18)}}的其他基金
COVID-19, heavy drinking and alcohol use disorders: a national study of Veterans Administration patients
COVID-19、酗酒和酒精使用障碍:一项针对退伍军人管理局患者的全国研究
- 批准号:
10371482 - 财政年份:2022
- 资助金额:
$ 18.72万 - 项目类别:
Scientific Conferences for The College on Problems of Drug Dependence (CPDD)
药物依赖问题学院科学会议(CPDD)
- 批准号:
10610865 - 财政年份:2021
- 资助金额:
$ 18.72万 - 项目类别:
Impact of Medical and Recreational Marijuana Laws On Cannabis, Opioids And Psychiatric Medications: National Study of VA Patients, 2000 - 2024
医用和娱乐大麻法对大麻、阿片类药物和精神药物的影响:2000 年至 2024 年退伍军人事务部患者的全国研究
- 批准号:
10393578 - 财政年份:2019
- 资助金额:
$ 18.72万 - 项目类别:
Impact of Medical and Recreational Marijuana Laws On Cannabis, Opioids And Psychiatric Medications: National Study of VA Patients, 2000 - 2024
医用和娱乐大麻法对大麻、阿片类药物和精神药物的影响:2000 年至 2024 年退伍军人事务部患者的全国研究
- 批准号:
10612385 - 财政年份:2019
- 资助金额:
$ 18.72万 - 项目类别:
Drinking levels (binge, volume) and alcohol consequences: using national data to identify clinical trial endpoints - Administrative Supplement
饮酒水平(酗酒、饮酒量)和酒精后果:使用国家数据确定临床试验终点 - 行政补充
- 批准号:
10228425 - 财政年份:2016
- 资助金额:
$ 18.72万 - 项目类别:
Drinking levels (binge, volume) and alcohol consequences: using national data to identify clinical trial endpoints
饮酒水平(酗酒、饮酒量)和酒精后果:使用国家数据确定临床试验终点
- 批准号:
9883624 - 财政年份:2016
- 资助金额:
$ 18.72万 - 项目类别:
Drinking levels (binge, volume) and alcohol consequences: using national data to identify clinical trial endpoints
饮酒水平(酗酒、饮酒量)和酒精后果:使用国家数据确定临床试验终点
- 批准号:
9440313 - 财政年份:2016
- 资助金额:
$ 18.72万 - 项目类别:
HealthCall: Enhancing brief intervention for HIV primary care alcohol dependence
HealthCall:加强对艾滋病毒初级保健酒精依赖的短期干预
- 批准号:
9317400 - 财政年份:2014
- 资助金额:
$ 18.72万 - 项目类别:
HealthCall: Enhancing brief intervention for HIV primary care alcohol dependence
HealthCall:加强对艾滋病毒初级保健酒精依赖的短期干预
- 批准号:
8731034 - 财政年份:2014
- 资助金额:
$ 18.72万 - 项目类别:
HealthCall: Enhancing brief intervention for HIV primary care alcohol dependence
HealthCall:加强对艾滋病毒初级保健酒精依赖的短期干预
- 批准号:
8932642 - 财政年份:2014
- 资助金额:
$ 18.72万 - 项目类别:
相似国自然基金
锌离子转运蛋白SLC39A1在急性呼吸窘迫综合征中的作用和机制
- 批准号:32371177
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
蜗牛粘液糖胺聚糖影响中性粒细胞粘附和迁移在治疗急性呼吸窘迫综合征中的作用研究
- 批准号:82360025
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
β-catenin诱导调节性T细胞代谢重编程及亚型转化在急性呼吸窘迫综合征的作用及机制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
特络细胞源性外泌体经JAK/STAT-miRNA-E2F轴修复肺血管改善急性呼吸窘迫综合征的机制研究
- 批准号:82272230
- 批准年份:2022
- 资助金额:52.00 万元
- 项目类别:面上项目
探索在急性呼吸窘迫综合征动物模型和患者长时间俯卧位通气过程中动态滴定呼气末正压的意义
- 批准号:82270081
- 批准年份:2022
- 资助金额:76 万元
- 项目类别:面上项目
相似海外基金
MLL1 drives collaborative leukocyte-endothelial cell signaling and thrombosis after coronavirus infection
MLL1在冠状病毒感染后驱动白细胞-内皮细胞信号传导和血栓形成
- 批准号:
10748433 - 财政年份:2023
- 资助金额:
$ 18.72万 - 项目类别:
Elucidating the immunology of autoantibody formation and function in COVID-19
阐明 COVID-19 中自身抗体形成和功能的免疫学
- 批准号:
10639707 - 财政年份:2023
- 资助金额:
$ 18.72万 - 项目类别:
Development of antibodies to specific cell surface markers to assess macrophage polarization during Adenovirus 14 and 14p1 infection in the Syrian hamster
开发针对特定细胞表面标记物的抗体,以评估叙利亚仓鼠腺病毒 14 和 14p1 感染期间的巨噬细胞极化
- 批准号:
10725702 - 财政年份:2023
- 资助金额:
$ 18.72万 - 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
- 批准号:
10591804 - 财政年份:2023
- 资助金额:
$ 18.72万 - 项目类别: